|
|
|
|
|
|
|
|
|
|
The presentations include an oral presentation of final data from the Company's Phase 2 trial of voreloxin in ovarian cancer....
Monday, April 19, 2010
financial news: Abstracts Highlighting Sunesis' Phase 2 Voreloxin Data Accepted for Presentation at 2010 ASCO Meeting
The presentations include an oral presentation of final data from the Company's Phase 2 trial of voreloxin in ovarian cancer....
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.